Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Direct oral anticoagulants and obesity: one size fits all?

den Exter PL, Huisman MV.

Lancet Haematol. 2019 Jul;6(7):e341-e342. doi: 10.1016/S2352-3026(19)30092-4. Epub 2019 May 24. No abstract available.

PMID:
31133410
2.

Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis.

Burr N, Lummis K, Sood R, Kane JS, Corp A, Subramanian V.

Lancet Gastroenterol Hepatol. 2017 Feb;2(2):85-93. doi: 10.1016/S2468-1253(16)30162-5. Epub 2016 Nov 16. Review.

3.

Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.

Marcy TR, Truong T, Rai A.

Consult Pharm. 2015 Nov;30(11):644-56. doi: 10.4140/TCP.n.2015.644. Review.

PMID:
26629800
4.

The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory.

Seheult JN, Meyer MP, Bontempo FA, Chibisov I.

Am J Clin Pathol. 2017 Jun 1;147(6):632-640. doi: 10.1093/ajcp/aqx035.

PMID:
28525532
5.

Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.

Glikson E, Chavkin U, Madgar O, Sagiv D, Nakache G, Yakirevitch A, Wolf M, Alon EE.

Laryngoscope. 2019 Jan;129(1):119-123. doi: 10.1002/lary.27400. Epub 2018 Oct 16.

PMID:
30325496
6.

A retrospective analysis of the periprocedural management of oral anticoagulants in patients undergoing interventional radiology procedures.

Marsh K, Ahuja T, Raco V, Green D, Sista AK, Papadopoulos J.

J Thromb Thrombolysis. 2018 Nov;46(4):451-460. doi: 10.1007/s11239-018-1740-0.

PMID:
30225669
7.

Oral Anticoagulants: The Move Beyond Warfarin.

Carroll VS, Frei J.

J Neurosci Nurs. 2016 Jul-Aug;48(4):177. doi: 10.1097/JNN.0000000000000230. No abstract available.

PMID:
27254485
8.

Anticoagulants: What is new and what is the standard?

Lesko LJ.

Clin Pharmacol Ther. 2016 Aug;100(2):126-8. doi: 10.1002/cpt.400. Epub 2016 Jun 24.

PMID:
27197625
9.

New oral anticoagulants: which one should my patient use?

Weitz JI, Gross PL.

Hematology Am Soc Hematol Educ Program. 2012;2012:536-40. doi: 10.1182/asheducation-2012.1.536. Review.

PMID:
23233631
10.

Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.

Alzghari SK, Seago SE, Garza JE, Hashimie YF, Baty KA, Evans MF, Shaver C, Herrington JD.

J Oncol Pharm Pract. 2018 Oct;24(7):494-500. doi: 10.1177/1078155217718382. Epub 2017 Jul 16. Erratum in: J Oncol Pharm Pract. 2019 Jan;25(1):255.

PMID:
28714376
11.

Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.

Wang KL, Chiu CC, Giugliano RP, Tan DS, Lin CY, Lai EY, Goto S, Chiang CE.

J Stroke Cerebrovasc Dis. 2018 Apr;27(4):857-864. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.027. Epub 2017 Nov 26. Review.

PMID:
29239808
12.

Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.

Morishima Y, Honda Y, Kamisato C, Shibano T.

Thromb Res. 2013 Aug;132(2):234-9. doi: 10.1016/j.thromres.2013.05.020. Epub 2013 Jun 12.

PMID:
23768448
13.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.

Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042.

PMID:
20934556
14.

PURLs: Direct oral anticoagulants or warfarin for A fib?

Lyon C, Reed A, Prasad S.

J Fam Pract. 2017 Aug;66(8):518-519.

15.

Pharmacology of the new target-specific oral anticoagulants.

Cabral KP.

J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. Review.

PMID:
23645472
16.

Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.

Hasan SS, Kow CS, Curley LE, Baines DL, Babar ZU.

Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):371-377. doi: 10.1080/14737167.2018.1474101. Epub 2018 May 9. Review.

PMID:
29741099
17.

Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin
.

Adachi T, Hoshino H, Takagi M, Fujioka S; Saiseikai Stroke Research Group.

Cerebrovasc Dis Extra. 2017;7(1):62-71. doi: 10.1159/000462985. Epub 2017 Apr 3.

18.

Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.

Cabral KP, Ansell J.

Nat Rev Cardiol. 2012 Feb 28;9(7):385-91. doi: 10.1038/nrcardio.2012.19. Review.

PMID:
22371104
19.

Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.

Pignatelli P, Pastori D, Bartimoccia S, Menichelli D, Vicario T, Nocella C, Carnevale R, Violi F.

Pharmacol Res. 2016 Nov;113(Pt A):484-489. doi: 10.1016/j.phrs.2016.09.035. Epub 2016 Sep 28.

PMID:
27693274
20.

Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.

Xiang CL, Gong YZ, Zeng LJ, Wang R, Kea S, Chaudhary N, Tu RH, He Y.

Acta Cardiol. 2016 Jun;71(3):349-57. doi: 10.2143/AC.71.3.3152095. No abstract available.

PMID:
27594130

Supplemental Content

Support Center